The earnings call presents a balanced view with significant achievements in study enrollment and strategic partnerships, but it is tempered by financial challenges and delays in study results. The financial position is strong, yet there is an increased R&D expense and a net loss. The sentiment is mixed, reflecting both optimism about Seralutinib's potential and concerns about financial and operational timelines.

Company Guidance -

Q3 2025

During the Gossamer Bio Q1 2025 earnings call, significant guidance was provided on the progress of Seralutinib, particularly in the Phase III PROSERA study for pulmonary arterial hypertension (PAH). The company achieved a milestone by closing new patient screenings with 343 patients enrolled or scheduled to randomize, while targeting a demonstration of a significant treatment effect in the six-minute walk distance at 24 weeks. The study aims to complete by the fourth quarter, with top-line results expected in February 2026. The baseline characteristics of the enrolled patients, including a mean six-minute walk distance of 376 meters and an NT-proBNP level of 96 ng/L, align with targeted criteria to optimize treatment success. Additionally, 74% of enrolled patients are categorized as functional Class III, indicating a sicker population likely to show a more dramatic improvement. The company emphasized Seralutinib's potential for first-in-class treatment, leveraging its unique mechanism and promising safety profile to position it as a backbone therapy in PAH. Financially, Gossamer ended Q1 with $257.9 million in cash, projecting sufficient funds until the first half of 2027.

PROSERA Study Enrollment Success

Gossamer Bio achieved a significant milestone by nearing the completion of enrollment for the PROSERA study with 343 patients. The baseline characteristics of the patients are exactly as targeted, enhancing the likelihood of success.

Strong Financial Position

Gossamer Bio ended the quarter with $257.9 million in cash and cash equivalents, providing sufficient capital until the first half of 2027.

Potential Global Expansion

Seralutinib's potential for regulatory approval in Japan is supported by its orphan drug designation and participation of Japanese patients in the PROSERA study.

Strategic Partnership with Chiesi Group

The collaboration with Chiesi Group enables Seralutinib to immediately enter a global registrational Phase III study for PH-ILD, with a shared cost basis of 50-50.

Gossamer Bio (GOSS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GOSS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.18 / -	-0.14	―	―	―
Aug 05, 2025	2025 (Q2)	-0.18 / -0.17	0.22	-177.27% (-0.39)	―	―
May 15, 2025	2025 (Q1)	-0.19 / -0.16	-0.19	15.79% (+0.03)	―
Mar 13, 2025	2024 (Q4)	-0.17 / -0.15	-0.21	28.57% (+0.06)	―	―
Nov 07, 2024	2024 (Q3)	-0.15 / -0.14	-0.21	33.33% (+0.07)	―	―
Aug 12, 2024	2024 (Q2)	0.51 / 0.22	-0.45	148.89% (+0.67)	―	―
May 07, 2024	2024 (Q1)	-0.19 / -0.19	-0.52	63.46% (+0.33)	―	―
Mar 05, 2024	2023 (Q4)	-0.21 / -0.21	-0.59	64.41% (+0.38)	―	―
Nov 09, 2023	2023 (Q3)	-0.26 / -0.21	-0.65	67.69% (+0.44)	―	―
Aug 08, 2023	2023 (Q2)	-0.49 / -0.45	-0.74	39.19% (+0.29)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GOSS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$2.16	$1.98	-8.33%
May 15, 2025	$1.05	$1.04	-0.95%
Mar 13, 2025	$1.30	$1.45	+11.54%
Nov 07, 2024	$0.89	$0.88	-1.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Gossamer Bio Inc (GOSS) report earnings?

Gossamer Bio Inc (GOSS) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Gossamer Bio Inc (GOSS) earnings time?

Gossamer Bio Inc (GOSS) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GOSS EPS forecast?

GOSS EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing